BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014; 20(41): 15110-15118 [PMID: 25386059 DOI: 10.3748/wjg.v20.i41.15110]
URL: https://www.wjgnet.com/1007-9327/full/v20/i41/15110.htm
Number Citing Articles
1
Ryoichi Miyamoto, Yukio Oshiro, Naoki Sano, Satoshi Inagawa, Nobuhiro Ohkohchi. Remnant pancreatic volume as an indicator of poor prognosis in pancreatic cancer patients after resectionPancreatology 2019; 19(5): 716 doi: 10.1016/j.pan.2019.05.464
2
伟 王. Research Prospect of Adjuvant and Neoadjuvant Therapy for Pancreatic CancerAdvances in Clinical Medicine 2022; 12(12): 11459 doi: 10.12677/ACM.2022.12121651
3
Satoshi Okubo, Motohiro Kojima, Yoko Matsuda, Masayoshi Hioki, Yasuhiro Shimizu, Hirochika Toyama, Soichiro Morinaga, Naoto Gotohda, Katsuhiko Uesaka, Genichiro Ishii, Mari Mino-Kenudson, Shinichiro Takahashi. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinomaScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-53801-2
4
Makoto Nishikawa, Suefumi Aosasa, Tomoyuki Moriya, Takuji Noro, Kazuo Hase, Junji Yamamoto. The impact of postoperative adjuvant chemotherapy on the development of nonalcoholic fatty liver disease after pancreatoduodenectomyJournal of Surgical Research 2016; 205(1): 127 doi: 10.1016/j.jss.2015.12.013
5
Kosei Takagi, Takahito Yagi, Takehiro Tanaka, Yuzo Umeda, Ryuichi Yoshida, Daisuke Nobuoka, Takashi Kuise, Toshiyoshi Fujiwara. Primary pancreatic-type acinar cell carcinoma of the jejunum with tumor thrombus extending into the mesenteric venous system: a case report and literature reviewBMC Surgery 2017; 17(1) doi: 10.1186/s12893-017-0273-3
6
Yunlong Chen, Jiangning Gu, Menghong Yin, Chenqi Wang, Dan Chen, Lili Yang, Xiang Chen, Zhikun Lin, Jian Du, Shimeng Cui, Chi Ma, Haifeng Luo. Safety and efficacy of S1 monotherapy or combined with nab-paclitaxel in advanced elderly pancreatic cancer patientsMedicine 2021; 100(25): e26342 doi: 10.1097/MD.0000000000026342
7
S. Hoshimoto, S. Hishinuma, H. Shirakawa, M. Tomikawa, I. Ozawa, S. Wakamatsu, S. Hoshi, N. Hoshi, K. Hirabayashi, Y. Ogata. Reassessment of the clinical significance of portal–superior mesenteric vein invasion in borderline resectable pancreatic cancerEuropean Journal of Surgical Oncology (EJSO) 2017; 43(6): 1068 doi: 10.1016/j.ejso.2017.03.020
8
Aleksandra Adamska, Alice Domenichini, Marco Falasca. Pancreatic Ductal Adenocarcinoma: Current and Evolving TherapiesInternational Journal of Molecular Sciences 2017; 18(7): 1338 doi: 10.3390/ijms18071338
9
Shigeo Koido, Masato Okamoto, Shigetaka Shimodaira, Haruo Sugiyama. Wilms’ Tumor 1 (WT1)-Targeted Cancer Vaccines To Extend Survival for Patients with Pancreatic CancerImmunotherapy 2016; 8(11): 1309 doi: 10.2217/imt-2016-0031
10
Dietrich A. Ruess, Kivanc Görgülü, Sonja M. Wörmann, Hana Algül. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging ConceptsDrugs & Aging 2017; 34(5): 331 doi: 10.1007/s40266-017-0453-y
11
Ryoichi Miyamoto, Tatsuya Oda, Shinji Hashimoto, Tomohiro Kurokawa, Keisuke Kohno, Yoshimasa Akashi, Yusuke Ohara, Keiichi Yamada, Tsuyoshi Enomoto, Nobuhiro Ohkohchi. Platelet × CRP Multiplier Value as an Indicator of Poor Prognosis in Patients With Resectable Pancreatic CancerPancreas 2017; 46(1): 35 doi: 10.1097/MPA.0000000000000697
12
Akihito Machinaga, Yuichi Hori, Kazuya Shimizu, Kyohei Okahara, Emmy Yanagita, Makoto Miyoshi, Tomoo Itoh, Ken Sasai. Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer PatientsPancreas 2019; 48(10): 1294 doi: 10.1097/MPA.0000000000001438
13
Matthew J. Reilley, Gauri R. Varadhachary. Multimodality Management of Borderline Resectable Pancreatic Cancer2016; : 91 doi: 10.1007/978-3-319-22780-1_6
14
Tae Kim, Soyoung Shin, Jeong Shin, Jürgen Bulitta, Kwon-Yeon Weon, Sun Yoo, Gi-Young Park, Seok Jeong, Dong Kwon, Byung Min, Mi Woo, Beom Shin. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic ModelingMolecules 2017; 22(9): 1488 doi: 10.3390/molecules22091488
15
Xiaohui Zhang, Lisa Detering, Deborah Sultan, Hannah Luehmann, Lin Li, Gyu Seong Heo, Xiuli Zhang, Lanlan Lou, Patrick M. Grierson, Suellen Greco, Marianna Ruzinova, Richard Laforest, Farrokh Dehdashti, Kian-Huat Lim, Yongjian Liu. CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal AdenocarcinomaACS Nano 2021; 15(1): 1186 doi: 10.1021/acsnano.0c08185
16
Hong Zhu, Cheng Yi, Yaqin Zhao, Hongfeng Gou. Gemcitabine plus S-1 for metastatic pancreatic cancerMedicine 2018; 97(41): e12836 doi: 10.1097/MD.0000000000012836
17
Atsuhiko Ueda, Nozomu Sakai, Hideyuki Yoshitomi, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Shigetsugu Takano, Daisuke Suzuki, Shingo Kagawa, Takashi Mishima, Eri Nakadai, Masaru Miyazaki, Masayuki Ohtsuka. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?World Journal of Surgical Oncology 2019; 17(1) doi: 10.1186/s12957-019-1667-8
18
Tsuyoshi Kono, Masuo Kondoh, Daisuke Kyuno, Tatsuya Ito, Yasutoshi Kimura, Masafumi Imamura, Takayuki Kohno, Takumi Konno, Tomohisa Furuhata, Norimasa Sawada, Koichi Hirata, Takashi Kojima. Claudin‐4 binder C‐CPE 194 enhances effects of anticancer agents on pancreatic cancer cell lines via a MAPK pathwayPharmacology Research & Perspectives 2015; 3(6) doi: 10.1002/prp2.196
19
Scott D. Haller, Michael L. Monaco, Karim Essani. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic CancerViruses 2020; 12(11): 1318 doi: 10.3390/v12111318
20
Terumi Kamisawa, Laura D Wood, Takao Itoi, Kyoichi Takaori. Pancreatic cancerThe Lancet 2016; 388(10039): 73 doi: 10.1016/S0140-6736(16)00141-0
21
Mamoon Ur Rashid, Ishtiaq Hussain, Sundas Jehanzeb, Waqas Ullah, Saeed Ali, Akriti Gupta Jain, Ranjeet Kumar, Neelam Khetpal, Sarfraz Ahmad. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy2019; : 57 doi: 10.1016/B978-0-12-817661-0.00005-6
22
Juan Wei, XiaoFang Dong, FangMing Du, Sheng Tang, HangPing Wei. Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancerMedicine 2017; 96(51): e9338 doi: 10.1097/MD.0000000000009338
23
Weiting Liao, Jiaxing Huang, Guiqi Zhu, Jing Zhou, Feng Wen, Pengfei Zhang, Kexun Zhou, Qiuji Wu, Xinyuan Wang, Hongfeng Gou, Qiu Li. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trialExpert Review of Pharmacoeconomics & Outcomes Research 2020; 20(1): 133 doi: 10.1080/14737167.2020.1677155
24
Kimihiko Funahashi, Tetsuo Nemoto, Junichi Koike, Akiharu Kurihara, Hiroyuki Shiokawa, Mistunori Ushigome, Tomoaki Kaneko, Kenichiro Arai, Yasuo Nagashima, Takamaru Koda, Takayuki Suzuki, Satoru Kagami, Yu Suitsu, Hironori Kaneko, Toshikazu Shibuya. Chemoradiation therapy with S-1 for primary squamous cell carcinoma of the rectum: report of three casesSurgical Case Reports 2015; 1(1) doi: 10.1186/s40792-015-0025-5
25
Rosella Spadi, Federica Brusa, Agostino Ponzetti, Isabella Chiappino, Nadia Birocco, Libero Ciuffreda, Maria Antonietta Satolli. Current therapeutic strategies for advanced pancreatic cancer: A review for cliniciansWorld Journal of Clinical Oncology 2016; 7(1): 27-43 doi: 10.5306/wjco.v7.i1.27
26
Angel Cid-Arregui, Victoria Juarez. Perspectives in the treatment of pancreatic adenocarcinomaWorld Journal of Gastroenterology 2015; 21(31): 9297-9316 doi: 10.3748/wjg.v21.i31.9297
27
Atsushi Oba, Daisuke Ban, Susumu Kirimura, Keiichi Akahoshi, Yusuke Mitsunori, Satoshi Matsumura, Takanori Ochiai, Atsushi Kudo, Shinji Tanaka, Tanabe Minoru. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinomaJournal of Hepato-Biliary-Pancreatic Sciences 2016; 23(8): 480 doi: 10.1002/jhbp.366
28
Bo Li, Shuo Shen, Siting You, Guoxiao Zhang, Suizhi Gao, Xiaohan Shi, Huan Wang, Xiaoyi Yin, Xiongfei Xu, Shiwei Guo, Gang Jin. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinomaBMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08380-9
29
Yumi Harano, Akira Babazono, Takako Fujita, Peng Jiang. Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort studyJournal of Geriatric Oncology 2019; 10(3): 420 doi: 10.1016/j.jgo.2018.09.004
30
Yusuke Yamaoka, Tomohiro Yamaguchi, Yusuke Kinugasa, Akio Shiomi, Hiroyasu Kagawa, Yushi Yamakawa, Masakatsu Numata, Shinya Sugimoto, Kenichiro Imai, Kinichi Hotta, Keiko Sasaki. Adenocarcinoma arising from jejunal ectopic pancreas mimicking peritoneal metastasis from colon cancer: a case report and literature reviewSurgical Case Reports 2015; 1(1) doi: 10.1186/s40792-015-0118-1
31
Yasuhiro Hagiwara, Yasuo Ohashi, Takuji Okusaka, Hideki Ueno, Tatsuya Ioka, Narikazu Boku, Shinichi Egawa, Takashi Hatori, Junji Furuse, Kazuhiro Mizumoto, Shinichi Ohkawa, Taketo Yamaguchi, Kenji Yamao, Akihiro Funakoshi, Ann-Lii Cheng, Kiyohiro Kihara, Atsushi Sato, Masao Tanaka. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST studyESMO Open 2017; 2(1): e000151 doi: 10.1136/esmoopen-2016-000151
32
Se Jun Park, Hyunho Kim, Kabsoo Shin, Myung Ah Lee, Tae Ho Hong. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancerWorld Journal of Gastrointestinal Oncology 2019; 11(11): 1021-1030 doi: 10.4251/wjgo.v11.i11.1021
33
Hidenori Ando, Kiyoshi Eshima, Tatsuhiro Ishida. Neutralization of Acidic Tumor Microenvironment (TME) with Daily Oral Dosing of Sodium Potassium Citrate (K/Na Citrate) Increases Therapeutic Effect of Anti-cancer Agent in Pancreatic Cancer Xenograft Mice ModelBiological and Pharmaceutical Bulletin 2021; 44(2): 266 doi: 10.1248/bpb.b20-00825
34
Kiyotsugu Iede, Terumasa Yamada, Ryo Kato, Masami Ueda, Yujiro Tsuda, Shinsuke Nakashima, Katsuya Ohta, Jin Matsuyama, Masakazu Ikenaga, Shusei Tominaga. Efficacy of S‐1 in second‐line chemotherapy after nab‐paclitaxel plus gemcitabine for patients with advanced pancreatic cancerCancer Reports 2020; 3(2) doi: 10.1002/cnr2.1215
35
Si Sun, Hui Yu, Huijie Wang, Hai Zhang, Xianghua Wu, Jialei Wang, Jianhua Chang. Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal CarcinomaOncology Research and Treatment 2019; 42(3): 115 doi: 10.1159/000495700